DelveInsight’s, “Encephalopathy Pipeline Insight, 2023” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in Encephalopathy pipeline landscape. It covers the Encephalopathy pipeline drug profiles, including Encephalopathy clinical trials and nonclinical stage products. It also covers the Encephalopathy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

In the Encephalopathy Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, Encephalopathy clinical trials studies, Encephalopathy NDA approvals (if any), and product development activities comprising the technology, Encephalopathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Key takeaways from the Encephalopathy Pipeline Report

 

• DelveInsight’s Encephalopathy pipeline report depicts a robust space with 70+ active players working to develop 70+ pipeline therapies for Encephalopathy treatment.

 

• The leading Encephalopathy Companies includes Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, and others.

 

• Promising Encephalopathy Pipeline Therapies includes TAK-935, VSL#3, Prospective Phase Rifaximin-α 550mg, Retrospective Phase, AST-120, Rifaximin, and others.

 

• The Encephalopathy companies and academics are working to assess challenges and seek opportunities that could influence Encephalopathy R&D. The Encephalopathy pipeline therapies under development are focused on novel approaches to treat/improve Encephalopathy.

 

To explore more information on the latest breakthroughs in the Encephalopathy Pipeline treatment landscape of the report, click here @ Encephalopathy Pipeline Outlook

 

 

Encephalopathy Overview

Encephalopathy is a broad term used to describe abnormal brain function or brain structure. (Encephalo= brain + pathy= disorder). The abnormality may be transient, recurrent, or permanent. The loss of brain function may be reversible, static and stable, or progressive with increasing loss of brain activity over time. There are two main types of encephalopathy: reversible and irreversible. Reversible causes include: Hepatic encephalopathy, Hashimoto’s encephalopathy, metabolic encephalopathy, infections of the brain, such as encephalitis or meningitis, or in another part of the body, such as a urinary tract infection. An extreme response to an infection, called sepsis, can also lead to encephalopathy.

 

Latest Developmental Activities in the Encephalopathy Treatment Landscape

 

• Xenon has received Fast Track designation and Orphan Drug Designation for XEN496 for the treatment of seizures associated with KCNQ2-DEE from the U.S. Food and Drug Administration (FDA), as well as orphan medicinal product designation from the European Commission.

 

• Rebiotix Inc., a Ferring Company, has leveraged its clinical, manufacturing and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455.Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Hepatic Encephalopathy.

 

For further information, refer to the detailed Encephalopathy Unmet Needs, Encephalopathy Market Drivers, and Encephalopathy Market Barriers, click here for Encephalopathy Ongoing Clinical Trial Analysis

 

Encephalopathy Emerging Drugs Profile

 

XEN496: Xenon Pharmaceuticals

XEN496, a Kv7 potassium channel opener, is a proprietary pediatric formulation of the active ingredient ezogabine being developed for the treatment of KCNQ2 developmental and epileptic encephalopathy (KCNQ2-DEE).Xenon has received Fast Track designation and Orphan Drug Designation for XEN496 for the treatment of seizures associated with KCNQ2-DEE from the U.S. Food and Drug Administration (FDA), as well as orphan medicinal product designation from the European Commission.

 

AXA 1665: Axcella Health

AXA1665 is an EMM composition of 8 amino acids and derivatives that targets three key nodes: ammonia toxicity, amino acid imbalance, and muscle wasting. Asp and Orn are intended to promote the function of the urea cycle. AXA1665 is designed to support pathways related to ammonia handling: Asp and Orn promote the function of the urea cycle and improved muscle mass and function promote ammonia handling within skeletal muscle. Currently, the drug is in Phase II stage of development for the treatment of Hepatic Encephalopathy.

 

RBX 7455: Rebiotix

Rebiotix Inc., a Ferring Company, has leveraged its clinical, manufacturing and regulatory experience with RBX2660 to develop the first of its kind non-frozen, room temperature stable oral microbiota-based formulation under the MRT™ drug platform, known as RBX7455.Currently, the drug is in Phase II stage of clinical trial evaluation for the treatment of Hepatic Encephalopathy.

 

Encephalopathy Pipeline Therapeutics Assessment

There are approx. 70+ key companies which are developing the therapies for Encephalopathy. The companies which have their Encephalopathy drug candidates in the most advanced stage, i.e. phase III include, Xenon Pharmaceuticals.

 

Encephalopathy Pipeline: Phases

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Request a sample and discover the recent advances in Encephalopathy Ongoing Clinical Trial Analysis and Medications, click here @ Encephalopathy Treatment Landscape

 

Scope of the Encephalopathy Pipeline Report

 

• Coverage- Global
• Encephalopathy Companies- includes Xenon Pharmaceuticals, Rebiotix, Axcella Health, Neurocrine Biosciences, Takeda, Praxis Precision Medicines, Stoke Therapeutics, Longboard Pharmaceuticals, Knoop Biosciences, Praxis Precision Medicines, Q-State Biosciences, Inc, Ocera Therapeutics, and others.
• Encephalopathy Pipeline Therapies- TAK-935, VSL#3, Prospective Phase Rifaximin-α 550mg, Retrospective Phase, AST-120, Rifaximin, and others.
• Encephalopathy Pipeline Segmentation: Product Type, Molecule Type, Route of Administration, Mechanism of Action

 

Dive deep into rich insights for drugs for Encephalopathy Market Drivers and Encephalopathy Market Barriers, click here @ Encephalopathy Unmet Needs and Analyst Views

 

Table of Content

1. Introduction
2. Executive Summary
3. Encephalopathy: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Encephalopathy– DelveInsight’s Analytical Perspective
7. Late Stage Products (Phase III)
8. XEN496: Xenon Pharmaceuticals 
9. Drug profiles in the detailed report…..
10. Mid Stage Products (Phase II)
11. RBX 7455: Rebiotix
12. Drug profiles in the detailed report…..
13. Early Stage Products (Phase I)
14. Drug Name: Company Name
15. Drug profiles in the detailed report…..
16. Preclinical and Discovery Stage Products
17. Drug Name; Company Name
18. Drug profiles in the detailed report…..
19. Inactive Products
20. Encephalopathy Key Companies
21. Encephalopathy Key Products
22. Encephalopathy – Unmet Needs
23. Encephalopathy – Market Drivers and Barriers
24. Encephalopathy – Future Perspectives and Conclusion
25. Encephalopathy Analyst Views
26. Encephalopathy Key Companies
27. Appendix

 

Got Queries? Find out the related information on Encephalopathy Mergers and acquisitions, Encephalopathy Licensing Activities @ Encephalopathy Emerging Drugs, and Recent Trends

Media Contact
Company Name: DelveInsight
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV 89107
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services